FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* COLEMAN KIRK ALLEN						2. Issuer Name and Ticker or Trading Symbol TFF Pharmaceuticals, Inc. [TFFP]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
(Last)	(F	First)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 11/10/2020							×		Officer (give title			specify		
2600 VIA FORTUNA, SUITE 360														CFO, S	CFO, Secretary, and Treasurer				
(Street)						4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Ind Line)	6. Individual or Joint/Group Filing (Check Applicable Line)					
AUSTIN	Т	X	78746										Form filed by One Reporting Person				n		
(City)	(9	State)	(Zip)		-								Form filed by More than One Reporting Person						
		Table I	- Non-l	Deriva	tive S	Sec	uri	ties Acc	quired	, Di	sposed o	f, or B	enefic	ally Ow	ned				
Date			Date	e I onth/Day/Year) a		2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Instr.		4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4			and 5) Securitie Beneficia Owned Fo		Form:	Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount	(A) or (D)	Price	Reported Transaction (Instr. 3 a				(instr. 4)	
Common Stock 11/10/2					0/2020	2020		М		15,000(1)	Α	\$2.5	16,000			D			
Common Stock 11/				11/10	0/2020	2020		S		15,000(1)	D	\$15.117 1,0)00		D			
		Tabl						-		-	oosed of, converti			-	ed				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution any (Month/Da	Date, if	4. Transaction Code (Instr. 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficia Owned Following Reported	re es ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership		
					Code	v	(A)	(D)	Date Exercisab	- 1	Expiration Date	Title	Amount or Number of Shares		Transacti (Instr. 4)	ion(s)			
Stock Options (Right to	\$2.5	11/10/2020			М			15,000 ⁽¹⁾	04/11/20	20	04/11/2029	Common Stock	15,000	\$0	302,8	83	D		

Explanation of Responses:

1. The transactions reported by this Form 4 reflect the Reporting Person's exercise of options to purchase common shares pursuant to Rule 16b-3 under the Securities Exchange Act of 1934 and the Reporting Person's concurrent sale of the common shares acquired upon the exercise of the options.

/s/ Kirk Allen Coleman 11/13/2020

** Signature of Reporting Person Date

 $Reminder: Report \ on \ a \ separate \ line \ for \ each \ class \ of \ securities \ beneficially \ owned \ directly.$

- $\mbox{\ensuremath{^{\star}}}$ If the form is filed by more than one reporting person, $\it see$ Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.